- Home
- MDGL vs GWRE Comparison
MDGL vs GWRE Comparison
Compare MDGL & GWRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDGL | GWRE |
|---|---|---|
| Founded | 2011 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1B | 11.9B |
| IPO Year | 2005 | 2011 |
Fundamental Metrics
Financial Performance| Metric | MDGL | GWRE |
|---|---|---|
| Price | $508.53 | $112.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 14 |
| Target Price | ★ $674.45 | $251.31 |
| AVG Volume (30 Days) | 262.9K | ★ 2.0M |
| Earning Date | 05-06-2026 | 06-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 41.32 | ★ 1257.14 |
| EPS | N/A | ★ 1.26 |
| Revenue | $180,133,000.00 | ★ $719,514,000.00 |
| Revenue This Year | $58.39 | $22.67 |
| Revenue Next Year | $48.55 | $15.73 |
| P/E Ratio | ★ N/A | $87.76 |
| Revenue Growth | N/A | ★ 8.84 |
| 52 Week Low | $284.02 | $102.30 |
| 52 Week High | $615.00 | $272.60 |
Technical Indicators
Market Signals| Indicator | MDGL | GWRE |
|---|---|---|
| Relative Strength Index (RSI) | 53.75 | 39.77 |
| Support Level | $498.59 | N/A |
| Resistance Level | $540.72 | $147.35 |
| Average True Range (ATR) | 17.55 | 7.28 |
| MACD | 3.74 | -1.79 |
| Stochastic Oscillator | 70.79 | 21.83 |
Price Performance
Historical ComparisonAbout MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
About GWRE Guidewire Software Inc.
Guidewire Software provides cloud-based software solutions for property and casualty insurers. The flagship product, InsuranceSuite is a system of record and comprises ClaimCenter, a claims management system; PolicyCenter, a policy management system including policy definitions, quotas, issuance, maintenance, and renewal; and BillingCenter, for billing management, payment plans, and agent commissions. The company also offers InsuranceNow, a midmarket offering, as well as a variety of other add-on applications and services.